Zynerba Pharmaceuticals Inc

Most Recent

  • Woman looking out a window and Zynerba logo
    Healthcare

    Why Zynerba (ZYNE) Might Be a Risky Bet for Investors

    By Ambrish Shah
  • uploads///PE ratio
    Cannabis

    PE Ratio and the Basic Science of Stock Valuation

    Ratio analysis is a commonly used method of stock valuation. Among the most popular ratios, most investors tend to look at PE.

    By Mohit Oberoi, CFA
  • uploads///biology doctor health
    Company & Industry Overviews

    Zynerba Gets Another Boost with Addition to Russell Index

    Today, Zynerba Pharmaceuticals (ZYNE) announced its stock would be added to the Russell 2000 Index and the Russell 3000 Index.

    By Mohit Oberoi, CFA
  • uploads///analysis _
    Company & Industry Overviews

    Zynerba Pharmaceuticals Rises Due to Patent News

    Zynerba Pharmaceuticals (ZYNE) has risen 18.6% as of 10:40 AM EST on June 11. The stock has year-to-date gains of more than 300%.

    By Mohit Oberoi, CFA
  • uploads///part
    Company & Industry Overviews

    Zynerba Pharmaceuticals: Analysts See More Upside after the Rally

    So far, Zynerba Pharmaceuticals (ZYNE) has seen an upwards price action of 265% in 2019. Analysts see more upside in the stock.

    By Mohit Oberoi, CFA
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.